Mirabegron and antimuscarinics for treating ureteral stent-related symptoms: a systematic review and meta-analysis of RCTs

Objective: We conducted a meta-analysis to assess the efficacy and safety of mirabegron (50 mg/day) and antimuscarinics in treating ureteral stent-related symptoms (SRSs). Methods: All randomized controlled trials (RCTs) were identified by searching PubMed, Embase, Web of Science, and Cochrane Libra...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Youyi, Li, Qi, Zou, Qingsong, Cui, Yuanshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618993/
https://www.ncbi.nlm.nih.gov/pubmed/37920205
http://dx.doi.org/10.3389/fphar.2023.1266636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618993/
https://www.ncbi.nlm.nih.gov/pubmed/37920205
http://dx.doi.org/10.3389/fphar.2023.1266636

Ejemplares similares